The Evolving Role of Immune Checkpoint Inhibitors in the Treatment of Triple-Negative Breast Cancer

Abstract: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer for which chemotherapy had been the only active treatment option once metastatic disease developed. […]

Reversing Resistance to Checkpoint Inhibitors and Targeted Therapy in Metastatic Melanoma

H&O How often do patients with metastatic melanoma experience primary or secondary resistance to checkpoint inhibitors? MS An estimated 40% to 50% of patients with […]

Toxicities of Checkpoint Inhibitors: Causes and Management

H&O What are some of the approved checkpoint inhibitors? MP The US Food and Drug Administration (FDA)-approved checkpoint inhibitors fall into 2 broad categories: the […]

Hem/Onc News

Aspirin Linked to Higher Rate of Cancer-Related Mortality Aspirin causes a slight increase in the risk of cancer-related mortality—although without an increase in cancer cases—when taken […]

Recent Advances in the Cellular and Molecular Understanding of Myelodysplastic Syndromes: Implications for New Therapeutic Approaches

Abstract: It has been more than 10 years since any new disease-modifying therapies have received regulatory approval for indications related to myelodysplastic syndromes (MDS). Advances […]

Highlights in Kidney Cancer From the 2017 American Society of Clinical Oncology Annual Meeting

1From the 2017 American Society of Clinical Oncology Annual Meeting June 2-6, 2017 • Chicago, Illinois Adjuvant Pazopanib Does Not Extend Disease-Free Survival in Locally Advanced […]

Immunotherapy in Urothelial Cancer, Part 1: T-Cell Checkpoint Inhibition in Advanced or Metastatic Disease

Abstract: Cancer of the urothelium is the sixth most common cancer in the United States and is seen predominantly in men. Most cases of this […]